Search Results - "Camacho, Elber S."

Bendamustine in Patients With Rituximab-Refractory Indolent and Transformed Non-Hodgkin's Lymphoma: Results From a Phase II Multicenter, Single-Agent Study by Friedberg, Jonathan W, Cohen, Philip, Chen, Ling, Robinson, K Sue, Forero-Torres, Andres, La Casce, Ann S, Fayad, Luis E, Bessudo, Alberto, Camacho, Elber S, Williams, Michael E, van der Jagt, Richard H, Oliver, Jennifer W, Cheson, Bruce D

“…Bendamustine hydrochloride is an alkylating agent with novel mechanisms of action. This phase II multicenter study evaluated the efficacy and toxicity of…”
Get full text

Extended follow‐up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma by Jagannath, Sundar, Durie, Brian G. M., Wolf, Jeffrey Lee, Camacho, Elber S., Irwin, David, Lutzky, Jose, McKinley, Marti, Potts, Phyllis, Gabayan, Afshin Eli, Mazumder, Amitabha, Crowley, John, Vescio, Robert

“…Summary High‐quality response to multiple myeloma (MM) therapy can be predictive for improved outcomes. Novel agents may improve the depth of responses and…”
Get full text

A phase III, randomized, double-blind study of single-dose intravenous fosaprepitant in preventing chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy by Rapoport, Bernardo Leon, Weinstein, Cindy, Camacho, Elber S., Khanani, Saleem A., Beckford-Brathwaite, Elizabeth, Kevill, Lydia, Vallejos, Waldimir, Liang, Li Wen, Noga, Stephen Joseph

“…Abstract only…”
Get full text

A Multi-Center Phase 1b, Open-Label, Dose-Finding Pilot Study to Evaluate the Combination of Carfilzomib and Cyclophosphamide with Dexamethasone (CCyD) Prior to Autologous Stem Cell Transplant (ASCT) in Patients with Transplant Eligible Newly Diagnosed Multiple Myeloma by Bensinger, William I., Vescio, Robert, Gasparetto, Cristina, Camacho, Elber S., Nath, Rajneesh, Gomes, Christina L., Smith, David D., Shah, Jatin J., Durie, Brian G.M.

“…Background: Carfilzomib is an epoxy ketone, second generation proteasome inhibitor approved for the treatment of relapsed and refractory multiple myeloma. It…”
Get full text

Phase III design for a trial of single-dose fosaprepitant (FA) in preventing chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC) by Noga, Stephen Joseph, Weinstein, Cindy, Camacho, Elber S, Khanani, Saleem A, Beckford-Brathwaite, Elizabeth, Vallejos, Waldimir, McGowan, Kelly, Tamburri, Grace, Force, Joanne, Taylor, Arlene

“…Abstract only…”
Get full text

A Phase II Study of Bortezomib (Velcade®), Cyclophosphamide (Cytoxan®), Thalidomide (Thalomid®) and Dexamethasone as First-Line Therapy for Multiple Myeloma by Bensinger, William, Jagannath, Sundar, Vescio, Robert, Camacho, Elber S., Wolf, Jeffrey Lee, Irwin, David H, Capo, Gerardo, McKinley, Marti, Potts, Phyllis, Vesole, David H., Mazumder, Amitabha, Esseltine, Dixie-Lee, Becker, Pamela, Crowley, John, Durie, Brian GM

“…Background: This phase II trial evaluated the response rate of sequential bortezomib (VELCADE®), cyclophosphamide (Cytoxan®), and dexamethasone ([VCD]; 3…”
Get full text

Bendamustine in Patients With Rituximab-Refractory Indolent and Transformed Non-Hodgkin's Lymphoma : Results From a Phase II Multicenter, Single-Agent Study Authors'reply by FRIEDBERG, Jonathan W, COHEN, Philip, VAN DER JAGT, Richard H, OLIVER, Jennifer W, CHESON, Bruce D, LING CHEN, ROBINSON, K. Sue, FORERO-TORRES, Andres, LA CASCE, Ann S, FAYAD, Luis E, BESSUDO, Alberto, CAMACHO, Elber S, WILLIAMS, Michael E

Get full text

Long-Term Follow-Up of Patients Treated with Bortezomib Alone and in Combination with Dexamethasone as Frontline Therapy for Multiple Myeloma by Jagannath, Sundar, Durie, Brian G.M., Wolf, Jeffrey Lee, Camacho, Elber S., Irwin, David, Lutzky, Jose, McKinley, Marti, Gabayan, Afshin Eli, Mazumder, Amitabha, Crowley, John, Vescio, Robert

“…Introduction: Novel therapeutic agents, such as bortezomib (VELCADE®; btz), thalidomide, and lenalidomide, are being used in combination with dexamethasone…”
Get full text

Bendamustine HCl (TREANDATM) Treatment Results in High Rates of Objective Response in Patients with Rituximab-Refractory and Alkylator-Refractory Indolent B-Cell Non-Hodgkin's Lymphoma (NHL): Results from a Phase II Multicenter Single-Agent Study (SDX-105-01) by Friedberg, Jonathan W., Cohen, Philip, Cheson, Bruce D., Robinson, K. Sue, Forero-Torres, Andres, Fayad, Luis, La Casce, Ann S., Bessudo, Alberto, Camacho, Elber S., Williams, Michael E., van der Jagt, Richard H., Oliver, Jennifer, Benaim, Ely

“…Background: Bendamustine HCl (TreandaTM) is a multifunctional, alkylating agent with novel mechanisms of action. Unlike other commonly used chemotherapeutic…”
Get full text

Tamoxifen response following no response to orchiectomy in metastatic male breast cancer: a case report by Hilliard, D A, Wilbur, D W, Camacho, E S

“…A male patient with advanced breast cancer had no response to orchiectomy but subsequently enjoyed a 17-month partial response to tamoxifen 10 mg B.I.D. His…”
Get more information

DNCB reactivity and prognosis in 419 patients with malignant melanoma by Camacho, E S, Pinsky, C M, Braun, Jr, D W, Golbey, R B, Fortner, J G, Wanebo, H J, Oettgen, H F

“…Delayed cutaneous hypersensitivity to 2,3-dinitrochlorobenzene (DNCB) was tested in 419 patients with malignant melanoma to determine whether DNCB reactivity…”
Get more information